Skip to content
StockMarketAgent
Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

ESLA stock hub

Estrella Immunopharma, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

ESLAis not in this month’s coverageGet our monthly research letter — no spam
Fair value midpoint
n/a
Fair value pending
Upside to midpoint
n/a
Based on latest report
Confidence
n/a
Data quality and model convergence
Market cap
53.8M
NASDAQ
Market data

Live price

Current market quote for this ticker.

Current price
ESLA
In the news

Latest news · ESLA

Recent company headlines from major financial publishers.

Loading
Fetching the latest headlines.
Loading
Fetching the latest headlines.
Loading
Fetching the latest headlines.
Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming
DateLoading
Window
EPS estimate
Revenue estimate
Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a
P25 12.3P50 18.4P75 33.1
Trailing P/En/a
P25 14.9P50 23.2P75 38.5
ROEn/a
P25 -105.6P50 -46.5P75 -3.1
ROICn/a
P25 -63.1P50 -27.3P75 0.5
Benchmarks - 1M
S&P 500n/a
Nasdaq Compositen/a
Dow Jones Industrial Averagen/a
Russell 2000n/a
Indicator catalog

All ESLA market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields
150
Groups with data
11
Currency
USD
Showing 150 of 150 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

20
MetricValue
Cik
0001844417
Company name
Estrella Immunopharma, Inc.
Country
United States
Country code
US
Cusip
297584104
Enterprise value
$52.4M
Exchange
NASDAQ
Financial currency
USD
First seen
2026-05-09
Industry
Biotechnology
Isin
US2975841048
Last refreshed
2026-05-10
Market cap
$53.8M
Market cap category
Micro-Cap
Price
$1.26
Price currency
USD
Sector
Healthcare
Sic
2836
Symbol
ESLA
Website
https://www.estrellabio.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

1
MetricValue
Earnings Yield
-24.3%

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

5
MetricValue
Net Income
$-13.1M
Net Income Growth Quarters
1%
Net Income Growth Years
0%
ROA
-258.5
ROCE
126

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

5
MetricValue
Cagr1y
12.51%
Cagr3y
-50.96%
EPS Growth Quarters
1
EPS Growth Years
0
Revenue Growth Years
0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

15
MetricValue
Assets
$3.2M
Cash
$1.4M
Current Assets
$1.7M
Current Liabilities
$13.5M
Debt
$6,000
Equity
$-10.4M
Liabilities
$13.5M
Long Term Assets
$1.5M
Long Term Liabilities
$0
Net Cash
$1.4M
Net Cash By Market Cap
$2.56
Net Cash Growth
50.98%
Tangible Book Value
$-10.4M
Tangible Book Value Per Share
$-0.27
WACC
9.65

Liquidity

Current-asset coverage and working-capital efficiency metrics.

4
MetricValue
Current ratio
0.12
Net Working Capital
$-13.2M
Quick ratio
0.1
Working Capital
$-11.9M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

2
MetricValue
Buyback Yield
-1.63%
Dividend Yield
0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

36
MetricValue
1Y total return
12.5%
200-day SMA
1.41
3Y total return
-88.21%
50-day SMA
1.37
50-day SMA vs 200-day SMA
50under200
All Time High
33
All Time High Change
-96.18%
All Time High Date
2023-09-01
All Time Low
0.63
All Time Low Change
100%
All Time Low Date
2024-10-31
ATR
0.17
Beta
0.98
Beta1y
2.83
Beta2y
1.85
Ch YTD
-19.23
High
1.27
High52
3.15
High52 Date
2025-11-04
High52ch
-60%
Low
1.21
Low52
0.78
Low52 Date
2025-07-15
Low52ch
61.54%
Ma50ch
-7.83%
Price vs 200-day SMA
-10.57%
RSI
38.97
RSI Monthly
41.35
RSI Weekly
47.28
Sharpe ratio
0.62x
Sortino ratio
1.06
Total Return
-1.63%
Tr YTD
-19.23
Tr1m
-26.74%
Tr1w
-22.7%
Tr3m
-13.1%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

6
MetricValue
Analyst Count
1
Analyst Ratings
Strong Buy
Earnings EPS Estimate
$-0.12
Operating Income
$-13.1M
Price target
$8
Price Target Change
$535

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

10
MetricValue
Float
18,021,462%
Float Percent
42.24%
Shares Insiders
1.88%
Shares Institutions
2.47%
Shares Out
42,665,228
Shares Qo Q
1.96%
Shares Yo Y
1.63%
Short Float
1.47%
Short Ratio
1.53
Short Shares
0.62

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

46
MetricValue
Average Volume
45,299.15x
Bv Per Share
-0.27
Ch1m
-26.74
Ch1w
-22.7
Ch1y
12.5
Ch3m
-13.1
Ch3y
-88.21
Ch6m
-57
Change
-0.79%
Change From Open
0.8
Close
1.27
Days Gap
-1.57
Dollar Volume
54,008.1
Earnings Date
2026-05-26
Earnings Time
amc
EBIT
$-13.1M
EPS
$-0.35
F Score
1
Financing CF
2,253,065
Fiscal Year End
December
Founded
2,021
Income Tax
$838
Is Primary Listing
1
Is Spac
No
Last Earnings Date
2026-03-18
Last Report Date
2025-12-31
Last Split Type
Never
Last10k Filing Date
2026-03-18
Ma150
1.54
Ma150ch
-18.34%
Ma20
1.61
Ma20ch
-21.59%
Net CF
467,386
Next Earnings Date
2026-05-26
Open
1.25
Optionable
No
Position In Range
88.71
Post Close
1.26
Postmarket Change Percent
-5.32
Postmarket Price
$1.19
Price Date
2026-05-08
Relative Volume
0.95x
Share Based Comp
618,974
Tr6m
-57%
Us State
California
Volume
42,863.6
Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate
n/a
Named kill scenarios are reviewed before any bullish rating can stand.
Moat score
n/a
Business quality stays separate from stock attractiveness.
Forward P/E
n/a
Valuation uses the full report model stack, not a single multiple.
Next action
Research pending
Final action steps are kept in the recommendation tab.
Income

Does ESLA pay a dividend?

Capital-return profile for this ticker.

Performance

ESLA stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

1Y total return
+12.5%
S&P 500 1Y: n/a
3Y total return
-88.2%
S&P 500 3Y: n/a
5Y total return
n/a
S&P 500 5Y: n/a
10Y total return
n/a
S&P 500 10Y: n/a
Ownership

Who owns ESLA?

Insider, institutional, and short-interest positioning.

Institutional ownership
+2.5%
Float: +42.2% of shares outstanding
Insider ownership
+1.9%
Stake held by company insiders. Higher generally signals alignment.
Short interest
+1.5%
1.5 days to cover
Y/Y dilution
+1.6%
Negative means the company is buying back shares.
Technical

ESLA momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)
39.0
Neutral momentum band
Price vs 200-day MA
-10.6%
50/200-day relationship not available
Beta (5Y)
0.98
Moves roughly with the market
Sharpe ratio
0.62
Risk-adjusted return — higher is better; >1.0 is solid.
Questions

About ESLA

Hub-level FAQ points readers to the deeper analysis pages.

What is the current ESLA stock rating?

Estrella Immunopharma, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full ESLA analysis?

The full report lives at /stocks/ESLA/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for ESLA?

The latest report frames ESLA around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the ESLA page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.